|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the NRF2 rs6721961 polymorphism was significantly associated with oxidative stress, anti-oxidative status, and risk of newly-diagnosed T2DM.
|
26204833 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This case and control study assessed genetic variants of NFE2L2 for associations with T2DM and its complications in Han Chinese volunteers.
|
27374075 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus: is Nrf2 a potential target for the treatment?
|
21861804 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
None of these models could completely recapitulate the unexpected protection against obesity observed in the whole body Nrf2 knockout mice, but this study points out the differential roles that Nrf2 may play, beyond cytoprotection, in different target tissues and rather suggests systemic activation of the Nrf2 pathway as an effective means of prevention and treatment of obesity and type 2 diabetes.
|
29486138 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The reported amelioration of insulin resistance, β-cell dysfunction and diabetic complications by activated Nrf2 as well as the status quo of Nrf2 in precision medicine for DM are reviewed.
|
29289692 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
α-LA might be considered a useful therapeutic tool to prevent hepatic steatosis by incrementing antioxidant defense systems through Nrf2 and consequently decreasing oxidative stress and inflammation in type 2 diabetes.
|
30208622 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
We found that Th1/Th2 and oxidative stress markers were significantly elevated, whereas Nrf2 and its downstream targets were decreased in peripheral blood mononuclear cells (PBMCs) of DM subjects when compared with control.
|
29572460 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we tested whether SFN protects the heart from T2DM directly through Nrf2, MT, or both.
|
27903744 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
As our data show that this maintains glucose-stimulated insulin secretion, targeting Nrf2 might be suited to ameliorate progression of type 2 diabetes mellitus.
|
31827698 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Herein we systemically examined the role of Nrf2 in DN progression and its regulatory mechanism in a mouse model bearing type II diabetes and in cultured human renal mesangial cells (HRMCs).
|
25046864 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Activators of Nrf2 can be used therapeutically in association with inhibitors of AGE and cross-linking formation to normalize endothelial dysfunction in type 2 diabetes.
|
29085055 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results showed that monascin exerted anti-inflammatory and antioxidative effects mediated by Nrf2 to prevent the development of diseases such as type 2 diabetes caused by inflammation.
|
23331247 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Inhibition of HDAC3 may ameliorate T2DM-induced BBB permeability through Nrf2 activation.
|
31101061 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recently published in vitro and in vivo findings strongly suggest that BBB impairment and increased risk for stroke by tobacco smoke (TS) closely resemble that of type-2 diabetes (2DM) and develop largely in response to common key modulators such oxidative stress (OS), inflammation and alterations of the endogenous antioxidative response system (ARE) regulated by the nuclear factor erythroid 2-related factor (Nrf2).
|
28646795 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The nuclear factor-erythroid 2- (NF-E2-) related factor 2 (Nrf2) is abated and its ability to reduce oxidative stress is impaired in type 2 diabetes and obesity.
|
27274779 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus.
|
28913364 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we tested the hypothesis that recombinant FGF21 (rFGF21) administration may reduce type 2 diabetes (T2D)-induced BBB disruption via NF-E2-related factor-2 (Nrf2) upregulation.
|
30022432 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
<i>Ex vivo</i> experiments indicated that Nrf-2 and HO-1 expression is reduced in T2DM <i>versus</i> non-T2DM OA cartilage (0.57-fold Nrf-2 and 0.34-fold HO-1), and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) release was increased in samples with low HO-1 expression.
|
28684418 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
OxPAPC concentrations (in PBMC and plasma), MDA levels (in plasma), the expressions of the glucose-regulated protein 78 kDa (or BiP) as representative of UPR, and of the CCAAT/enhancer-binding protein homologous protein as representative of ER apoptosis were significantly higher (p < 0.01) in T2DM with respect to C. IkBα expression was significantly lower (p < 0.01) in T2DM as well as Nrf2 and HO-1.
|
25511473 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Therapeutic
|
disease |
RGD |
A novel natural Nrf2 activator with PPARγ-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia.
|
23954466 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we concluded that the activation of antioxidant Nrf2/HO-1 pathway potentiate the effects of CB2R agonists and might be suitable for the treatment of painful neuropathy linked to type 2 diabetes.
|
29143802 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This review focuses on the role that Nrf2/ARE-linked gene expression plays in regulating endothelial redox homeostasis in health and type 2 diabetes, highlighting recent evidence that Nrf2 may provide a therapeutic target for countering oxidative stress associated with vascular disease and aging.
|
20524845 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, we assessed the expression of Nrf2 and Keap1 immunohistochemically in 157 patients with type 2 diabetes who underwent breast cancer surgery with curative intent.
|
30803422 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
OP alleviated the T2DM characteristics through the activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3β) pathway, and enhanced the nuclear factor erythroid-2 (Nrf2) expression and promoted Nrf2-medicated heme oxygenase-1(HO-1) and superoxide dismutase 2 (SOD2) expression.
|
31108940 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, FJACP improves the indices of antioxidant and anti-inflammation status by activating Keap1 and Nrf2 via the upregulation of miR-424 in the patients with T2DM.
|
28642811 |
2017 |